Clene Inc. at ROTH Conference Transcript

Mar 13, 2023 / 07:30PM GMT
Jonathan Ashcoff - ROTH MKM - Analyst

Again, I'm Jonathan Ashcoff, Senior Biotechnology Analyst at ROTH MKM. And now with us we have Rob Etherington, the CEO of Clene Inc.

Rob Etherington - Clene Inc. - President & CEO

Thank you, Jonathan. Pleasure to be here.

Jonathan Ashcoff - ROTH MKM - Analyst

Welcome, Rob.

Questions and Answers:

Jonathan Ashcoff - ROTH MKM - Analyst

So let's discuss your main product, CNM-Au8. A lot of people are probably unfamiliar with it. How does it work? What makes it unique? Is this alchemy or is this really gold?

Rob Etherington - Clene Inc. - President & CEO

So it's a -- CNM-Au8 is a gold nanocrystal suspension. The only such drug of its type that we are aware where the therapy is the asset itself. In other words, there's gold nanocrystals that one could use for drug delivery, there's gold nanocrystals that one could use to paint an asset, another asset on, there's gold nanocrystals
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot